# Pelthos Therapeutics Inc. (PTHS)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/pelthos-therapeutics-inc/ JSON: https://steadybase.io/company/pelthos-therapeutics-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: Pelthos Therapeutics Inc.
- Ticker: PTHS (NYSE)
- SEC CIK: 0001919246
- Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
- Headquarters: Durham, NC
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: pelthos.com
- Investor relations: https://ir.pelthos.com
- LinkedIn: https://www.linkedin.com/company/pelthos
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $16.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/0001919246-26-000013-index.html
- Operating income: -$32.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/0001919246-26-000013-index.html
- Net income: -$43.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/0001919246-26-000013-index.html
- SG&A: $42.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 19, 2026). Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/0001919246-26-000013-index.html
- Employees: 92 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Shares outstanding: 3,828,469 as of Aug 10, 2026 (10-Q/A filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000111/0001919246-26-000111-index.html
- Auditor: Cbiz Cpas P.C., Hartford, Connecticut, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm

## Business

Pelthos Therapeutics Inc. (the “Company”) is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.S. Food and Drug Administration (“FDA”) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMI TM , XEPI ® , and XEGLYZE ® .

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $16.8M | -$32.4M | -$43.3M | $42.5M |
| Dec 31, 2024 | $0 | -$7.6M | -$8.0M | $6.4M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/pelthos-therapeutics-inc.json

## Officers and directors

- Scott M. Plesha, CEO and President. LinkedIn: https://linkedin.com/in/scott-plesha-63ba50b3. Source: 4/A filed Apr 1, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000044/0001919246-26-000044-index.htm
- Scott Plesha, Chief Executive Officer and President. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Knuettel Francis II, CFO, Treas & Secty. Source: Form 4 filed May 26, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000081/0001919246-26-000081-index.htm
- John M. Gay, Chief Financial Officer. Source: Form 3 filed Apr 20, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000063/0001919246-26-000063-index.htm
- Francis Knuettel II, Chief Financial Officer. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Sai Rangarao, Chief Commercial Officer. LinkedIn: https://linkedin.com/in/sai-rangarao-88635122. Source: 4/A filed Apr 1, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000041/0001919246-26-000041-index.htm
- Peter Greenleaf, Director (Chairman of the Board). Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Andrew Einhorn, Director. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Ezra Friedberg, Director. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Matthew Pauls, Director. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Richard Baxter, Director. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- Todd Davis, Director. Source: 10-K filed Mar 19, 2026, https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm

## Recent 8-K events

- Oct 30, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 3.03, Material modification to rights of security holders; Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 5.07, Submission of matters to a vote of security holders; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000110465926120457/tm2628523d1_8k.htm
- Oct 1, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000125/pths-20260929.htm
- Aug 13, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000112/pths-20260813.htm
- Aug 13, 2026: Item 4.02, Non-reliance on previously issued financial statements. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/pths-20260812.htm
- May 28, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000085/pths-20260528.htm
- May 21, 2026: Item 4.01, Changes in registrant's certifying accountant; Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000078/pths-20260515.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/pths-20260514.htm
- Apr 14, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000060/pths-20260414.htm
- Apr 10, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000058/pths-20260410.htm
- Mar 19, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/pths-20260319.htm

## Insider trades (Form 4)

- Oct 2, 2026: Peter Greenleaf (Director) sold 797 shares, about $16,872. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000131/0001919246-26-000131-index.htm
- Oct 2, 2026: Ezra M. Friedberg (Director) sold 558 shares, about $11,560. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000130/0001919246-26-000130-index.htm
- Oct 2, 2026: Matthew Pauls (Director) sold 786 shares, about $16,506. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000129/0001919246-26-000129-index.htm
- Jul 2, 2026: Ezra M. Friedberg (Director) sold 558 shares, about $14,556. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000102/0001919246-26-000102-index.htm
- Jul 2, 2026: Matthew Pauls (Director) sold 786 shares, about $20,564. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000101/0001919246-26-000101-index.htm
- Jul 2, 2026: Peter Greenleaf (Director) sold 797 shares, about $20,830. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000100/0001919246-26-000100-index.htm
- Jun 15, 2026: Ezra M. Friedberg (Director) sold 283 shares, about $7,723. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000093/0001919246-26-000093-index.htm
- Jun 11, 2026: Todd C. Davis (Director) bought 35,948 shares, about $999,822. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000088/0001919246-26-000088-index.htm
- May 22, 2026: Knuettel Francis II (CFO, Treas & Secty) sold 1,500 shares, about $40,260. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000081/0001919246-26-000081-index.htm
- Apr 2, 2026: Richard Malamut (Director) sold 590 shares, about $12,339. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000055/0001919246-26-000055-index.htm
- Apr 2, 2026: Ezra M. Friedberg (Director) sold 558 shares, about $11,670. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000054/0001919246-26-000054-index.htm
- Apr 2, 2026: Matthew Pauls (Director) sold 786 shares, about $16,440. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000053/0001919246-26-000053-index.htm
- Apr 2, 2026: Peter Greenleaf (Director) sold 797 shares, about $16,671. Source: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000052/0001919246-26-000052-index.htm
- Nov 25, 2025: Ezra M. Friedberg (Director) sold 10,000 shares, about $280,301. Source: https://www.sec.gov/Archives/edgar/data/1919246/000175392625001831/0001753926-25-001831-index.htm

## Latest filings

- 8-K filed Oct 30, 2026: https://www.sec.gov/Archives/edgar/data/1919246/000110465926120457/tm2628523d1_8k.htm
- 10-K filed Mar 19, 2026: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000013/pths-20251231.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000113/pths-20260630.htm
- DEF 14A filed Aug 18, 2026: https://www.sec.gov/Archives/edgar/data/1919246/000191924626000120/pths-20260818.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/